Daily Roundup

NEU.ASX SDV.ASX MYE.ASX EQR.ASX LNW.ASX

Neuren Pharmaceuticals is riding high on strong demand for its flagship drug. The company reported record Q2 DAYBUE net sales of US$125 million, marking a 30% jump from the same quarter last year. The real driver here is DAYBUE STIX, a new powder formulation that's resonating with patients—by the end of Q2, roughly 40% of all US DAYBUE patients were already using it. Looking ahead, Neuren expects a European launch in Q4 2026, and Japan trial results should arrive sometime between September and November. The company also received an upgraded royalty forecast based on its partner Acadia's improved full-year guidance.

SciDev is making its first move into the booming data centre space. The company has secured initial contracts with two of Australia's largest hyperscale data centre operators, covering design, consulting, and embedded engineering services. These deals are expected to generate around $0.5 million in revenue during the first half of FY27, with room for expansion down the line.

Over in mining services, Mastermyne Group landed a significant new contract with GM3 for the Dendrobium underground coal mine in New South Wales. The deal is worth an estimated $85 million over its initial two-year term, with the potential to balloon to $255 million if both two-year extension options are exercised. The contract will create more than 140 new roles and strengthens the company's order book heading into FY27.

EQ Resources, a global tungsten producer, hit a new revenue milestone in July. The company posted record revenue of A$51 million, fueled by a 36% surge in consolidated production to 14,255 mtu compared to June. Production gains were broad-based, with the Barruecopardo site jumping 48% and Mt Carbine climbing 16%. The company also achieved a record average realised price of US$2,386 per mtu.

Light & Wonder wrapped up a solid Q2 with net income climbing 26% to $120 million and consolidated AEBITDA rising 9% to $383 million. Revenue edged up 2% year-over-year to $828 million, with Gaming operations and iGaming both contributing to growth. Recurring revenue reached $580 million, up 6% annually. The company returned $134 million to shareholders through buybacks and maintained its full-year outlook for mid- to high-single-digit AEBITDA growth. Management is also targeting a net debt leverage ratio below 3.0x by the first half of 2027.